5517. Lisofylline
Nomenclature
CAS number: 100324-81-0
3,7-Dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-1H-purine-2,6-dione; 1-[(R)-5-hydroxyhexyl]theobromine; 1-(5R-hydroxyhexyl)-3,7-dimethylxanthine; CT-1501R; ProTec (Cell Therapeutics). C13H20N4O3; mol wt 280.32.
C 55.70%, H 7.19%, N 19.99%, O 17.12%.
Description and references
Methylxanthine that inhibits production of phosphatidic acid during the inflammatory response. Identification as metabolite of pentoxifylline: H.-J. Hinze et al., Arzneim.-Forsch. 22, 1144 (1972). Enantioselective process: W. Aretz et al., DE 3942872; eidem, US 5310666 (1991, 1994 both to Hoechst). Asymmetric synthesis: J. P. Klein et al., WO 9531450 (1995 to Cell Therapeutics). Study of mechanism of action in septic shock: G. C. Rice et al., Proc. Natl. Acad. Sci. USA 91, 3857 (1994). Enhancement of hematopoietic recovery following 5-fluorouracil treatment in mice: E. Clarke et al., Cancer Res. 56, 105 (1996).
Properties
mp 110°. [α]D20 5.6° (c = 6.7 in ethanol).Therapeutic Category
Immunomodulator.
Keywords
Immunomodulator